Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
32 papers
Some research suggests that whole-plant cannabis compounds (like THC, CBD, other cannabinoids, terpenes, and flavonoids) can interact so the plant’s effects differ from CBD alone. Healthline explains three CBD types — full-spectrum, broad-spectrum, and isolate — and notes legal, safety, and labeling limits. The article says there is evidence for…
The endocannabinoid system (ECS) is a widespread brain signaling system made of cannabinoid receptors, naturally made lipid messengers, and the enzymes that make and break those messengers. The two best-studied messengers are 2-AG and anandamide, and they are produced and degraded by different enzyme pathways. CB1 receptors are common in…
This review says cannabidiol (CBD) is a non‑psychoactive cannabis compound that has antioxidant and anti‑inflammatory actions in lab and some clinical studies. CBD can act directly to neutralize reactive molecules and indirectly by changing cell signals and antioxidant enzymes. Experiments in cells and animals show CBD lowers markers of oxidative…
This 2017 review of studies up to 2014 looked at how cannabis and related drugs affect sleep. The authors found early, mixed evidence: cannabidiol (CBD) showed possible benefit for insomnia and some sleep disorders, THC might make people fall asleep faster but could harm sleep quality over time, and some…
This review describes the endocannabinoid system (ECS) as a widespread network of natural cannabinoids, cannabinoid receptors (mainly CB1 and CB2), and the enzymes that make and break those chemicals. The ECS helps shape brain development and adjusts how neurons communicate. The authors note that THC is the main psychoactive part…
This brief review explains what is known about medical cannabis and its main chemicals. Cannabis has many natural compounds, and the two best-known are Δ9‑tetrahydrocannabinol (Δ9‑THC), which causes psychoactive effects, and cannabidiol (CBD), which does not. The authors describe possible medical uses (for pain, epilepsy, and neurodegenerative diseases) but say…
This laboratory study found that cannabidiol (CBD), a non‑psychoactive compound from Cannabis sativa, reduced fat production and inflammation in human sebaceous (oil) gland cells. The effects were seen in cultured human sebocytes and in human skin organ cultures, where CBD blocked the fat‑making (lipogenic) actions of several compounds. These results…
This webpage explains how DoktorABC offers medical cannabis services in Germany. You fill an online medical questionnaire, a licensed doctor reviews it, and may issue a prescription. The page also describes costs, delivery times, legal status, types of products, common effects of THC and CBD, and possible side effects.
In rats and mice that had brain lesions used to model Parkinson's disease, the plant compound Δ9-THCV reduced movement problems after a single dose and, with repeated dosing, reduced loss of dopamine-producing neurons in the brain region called the substantia nigra. Some effects seem linked to antioxidant actions and, in…
Researchers isolated a new natural cannabis compound called Δ9-tetrahydrocannabiphorol (Δ9-THCP) and its CBD counterpart (CBDP). In lab tests, Δ9-THCP bound very strongly to the human CB1 receptor (Ki = 1.2 nM) and caused THC-like effects in mice (less movement, pain relief, catalepsy, and lower body temperature). The authors say Δ9-THCP…
Cannabis makes more than 120 “minor” cannabinoids that appear in smaller amounts than THC and CBD and come from a parent compound called cannabigerolic acid (CBGA). Early lab and clinical work shows these minor cannabinoids can activate or block many biological targets (for example CB1 and CB2 receptors, TRP channels,…
This review looks at research on how cannabis and its active chemicals relate to psychosis. It says there are three patterns: short psychotic symptoms during intoxication, short psychosis that can last beyond intoxication (often resolving within a month in case reports), and persistent psychosis that is not clearly tied to…
